Lutetium
Supply Chain
Lutetium Supply Chain: From Mine to Market
Lutetium is the rarest naturally occurring lanthanide and follows the rare earth supply chain with China controlling ~95% of production. Separation of lutetium requires the most stages of solvent extraction of any rare earth due to its position at the end of the lanthanide series. Global production is only ~10 tonnes/year. Two emerging medical applications are driving increased interest: LSO/LYSO scintillation crystals for PET scanners (every modern PET scanner uses lutetium-based detectors) and Lu-177 radiopharmaceuticals for targeted cancer therapy. Novartis Pluvicto (Lu-177 PSMA for prostate cancer, >$1B annual sales) has made lutetium strategically important for the pharmaceutical industry.
Annual Production
10
tonnes
Top Producer
China
95% of global output
Global Reserves
Part of total REE reserves (rarest lanthanide)
Recycling Rate
0%
End-of-life recycling
Production Geography
Global Lutetium production is led by China, which accounts for approximately 95% of world output, followed by Myanmar. The full list of major producing nations includes China, Myanmar, Australia. This geographic concentration means that disruptions in key producing regions can have outsized impacts on global supply and pricing.
Extraction Methods
Lutetium is extracted using the following primary methods:
- Ion-adsorption clay leaching
- Byproduct of heavy REE separation
Processing and Intermediate Products
Lutetium is primarily sourced from Ion-adsorption clays, Xenotime. After extraction, the raw material undergoes multiple processing steps including beneficiation, chemical treatment, and refining to reach the purity levels required by downstream industries. Typical ore grades range from 0.001-0.005% Lu2O3.
Key Supply Chain Participants
The Lutetium supply chain involves these major companies:
China Southern Rare Earth Group
Primary global source of separated lutetium
Siemens Healthineers
Major PET scanner manufacturer using LSO/LYSO scintillation crystals containing lutetium
GE HealthCare
Produces PET scanners using lutetium-based scintillator detectors
Novartis
Markets Pluvicto (lutetium-177 PSMA), a radioligand therapy for metastatic prostate cancer approved in 2022
Supply Chain Vulnerabilities
Key vulnerabilities in the Lutetium supply chain include concentration of 95% of production in China, limited processing capacity diversification, and long lead times for new mining projects. The high supply risk rating reflects the severity of these concentration risks and the difficulty of rapidly establishing alternative supply sources.
More on Lutetium
Explore other aspects of the Lutetium value chain.
Uses & Applications
Explore uses & applications for Lutetium.
Mining & Processing
Explore mining & processing for Lutetium.
Refining & Grade Specs
Explore refining & grade specs for Lutetium.
Recycling
Explore recycling for Lutetium.
Substitutes
Explore substitutes for Lutetium.
Investing
Explore investing for Lutetium.
Return to the Lutetium hub page or browse the full Mineral Library.